Brimonidine Related Published Studies
Well-designed clinical trials related to Brimonidine (Ophthalmic)
Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs. [2009.09]
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. [2008.04]
Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK. [2008.04]
Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]
Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2%pirenzepineophthalmicgelinchildrenwithmyopia. [2008.03.21]
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. [2008.02]
Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. [2008.02]
Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. [2008.01]
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. [2007.12]
The systemic safety of bromfenac ophthalmic solution 0.09%. [2007.12]
The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. [2007.12]
Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. [2007.11]
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]
Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial. [2007.10]
Effect of Brimonidine Tartrate 0.15% on Scotopic Pupil-Controlled Trial. [2007.09.27]
Effect of prophylactic brimonidine instillation on bleeding during strabismus surgery in adults. [2007.09]
Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting. [2007.09]
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. [2007.09]
Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. [2007.07]
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. [2007.07]
Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. [2007.04]
Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. [2007.01]
Efficacy of topical ophthalmic prophylaxis in prevention of ophthalmia neonatorum. [2007.01]
Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery. [2007.01]
[Comparative clinical study of two dexamethasone phosphate-containing ophthalmics] [2007]
Does cerebral monitoring improve ophthalmic surgical operating conditions during propofol-induced sedation? [2006.11]
Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. [2006.09]
Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%. [2006.09]
The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. [2006.08]
Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. [2006.08]
Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy. [2006.06]
Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis. [2006.06]
Pharmacodynamics of a new ophthalmic mydriatic insert in healthy volunteers: potential alternative as drug delivery system prior to cataract surgery. [2006.06]
A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. [2006.05]
Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. [2006.05]
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. [2006.04]
Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma. [2006.04]
Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. [2006.04]
Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. [2006.03]
Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. [2006]
Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study. [2005.12]
Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study. [2005.12]
Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. [2005.11]
[Lavasept as an alternative to PVP-iodine as a preoperative antiseptic in ophthalmic surgery. Randomized, controlled, prospective double-blind trial] [2005.11]
Advantage of three dimensional animated teaching over traditional surgical videos for teaching ophthalmic surgery: a randomised study. [2005.11]
Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. [2005.11]
Advancing ophthalmic nursing practice through action research. [2005.11]
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]
The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. [2005.11]
Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. [2005.10]
A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. [2005.10]
Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery. [2005.09]
12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. [2005.09]
Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. [2005.09]
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. [2005.09]
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. [2005.08]
Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. [2005.08]
Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsification [ISRCTN34957881]. [2005.07.15]
Brimonidine versus dapiprazole: Influence on pupil size at various illumination levels. [2005.07]
The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. [2005.07]
Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. [2005.07]
A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]
Effectiveness of combined antibiotic ophthalmic solution in the treatment of hordeolum after incision and curettage: a randomized, placebo-controlled trial: a pilot study. [2005.05]
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. [2005.05]
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. [2005.05]
Changes in bacterial and fungal ocular flora of clinically normal horses following experimental application of topical antimicrobial or antimicrobial-corticosteroid ophthalmic preparations. [2005.05]
24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. [2005.04]
Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. [2005.04]
Pharmacokinetic and pharmacodynamic analysis of systemic effect of topically applied timolol maleate ophthalmic gelling vehicle (Rysmon TG). [2005.04]
Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy. [2005.03]
Effect of prophylactic brimonidine on bleeding complications after cataract surgery. [2005.03]
Characterization of the novel ophthalmic drug carrier Sophisen in two of its derivatives: 3A Ofteno and Modusik-A Ofteno. [2005.03]
Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. [2005.02]
Evaluation of a new preoperative ophthalmic solution. [2005.02]
Effects of a 0.9% sodium chloride ophthalmic solution on the ocular surface of symptomatic contact lens wearers. [2005.02]
Efficacy and safety of three ophthalmic inserts for topical anaesthesia of the cornea. An exploratory comparative dose-ranging, double-blind, randomized trial in healthy volunteers. [2005.02]
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. [2005.01]
Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. [2005.01]
Duration of effect and effect of multiple doses of topical ophthalmic 0.5% proparacaine hydrochloride in clinically normal dogs. [2005.01]
One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. [2005.01]
Well-designed clinical trials possibly related to Brimonidine (Ophthalmic)
Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. [2008.09]
I.V. ropivacaine compared with lidocaine for the treatment of tinnitus. [2008.08]
A Placebo-Controlled 3-Year Study of a Calcium Blocker on Visual Field and Ocular Circulation in Glaucoma with Low-Normal Pressure. [2008.07.30]
Peribulbar versus retrobulbar anaesthesia for cataract surgery. [2008.07.16]
Measurement of surgical stress in anaesthetized children. [2008.07.15]
Intranasal Mometasone Furoate Alleviates the Ocular Symptoms Associated with Seasonal Allergic Rhinitis: Results of a Post Hoc Analysis. [2008.07.12]
Vision screening for frail older people: a randomized trial. [2008.07.09]
A randomized, prospective, placebo-controlled clinical trial of a novel zinc-monocysteine compound in age-related macular degeneration. [2008.07]
Intranasal budesonide treatment for children with mild obstructive sleep apnea syndrome. [2008.07]
Corticocapsular cleavage during phacoemulsification: Viscodissection versus hydrodissection. Miyake-Apple view analysis. [2008.07]
DisCoVisc versus the soft-shell technique using Viscoat and Provisc in phacoemulsification: randomized clinical trial. [2008.07]
New technology for sizing the continuous curvilinear capsulorhexis: prospective trial. [2008.07]
Management of acute central retinal artery occlusion. [2008.07]
Randomized, prospective comparison of precut vs surgeon-dissected grafts for descemet stripping automated endothelial keratoplasty. [2008.07]
Macular morphology after cataract surgery with primary posterior capsulorhexis and posterior optic buttonholing. [2008.07]
Prevention of anterior capsule contraction by anterior capsule relaxing incisions with neodymium:yttrium-aluminum-garnet laser. [2008.07]
Efficacy and safety of purified botulinum toxin type A (Dysport((R))) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. [2008.07]
Prospective randomized comparison of one- versus two-site Phacotrabeculectomy two-year results. [2008.07]
Randomized trial of early phacoemulsification versus peripheral iridotomy to prevent intraocular pressure rise after acute primary angle closure. [2008.07]
Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. [2008.07]
|
